Kezdőlap › Multiplex mielóma › Tennessee › Nashville
Multiplex mielóma klinikai vizsgálatok: Nashville, TN
32 Multiplex mielóma vizsgálat keres résztvevőket Nashville és környéke (kb. 30 mérföldes körzetben) helyszínein. Nyissa meg a vizsgálatot, hogy lássa, ki csatlakozhat, és hogyan léphet kapcsolatba a csapattal.
Hivatalos vizsgálati szöveg (angol)
Vizsgálatra keres résztvevőket? Emelje ki az oldal tetején — $99 / 30 nap →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Toborzás folyamatban3. fázis
- Research Site, Nashville
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Toborzás folyamatban4. fázis
- Sarah Cannon Research Institute, Nashville
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Toborzás folyamatban3. fázis
- SCRI Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Toborzás folyamatban3. fázis
- Tennessee Oncology, PLLC, Nashville
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Toborzás folyamatban1. fázis
- Research Site, Nashville
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Toborzás folyamatban3. fázis
- Henry-Joyce Cancer Clinic, Nashville
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Toborzás folyamatban1/2. fázis
- Sarah Cannon Research Institute, Nashville
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Toborzás folyamatban2. fázis
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Toborzás folyamatban2/3. fázis
- SCRI Oncology Partners /ID# 278353, Nashville
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Toborzás folyamatban2. fázis
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Toborzás folyamatban2. fázis
- SCRI Oncology Partners, Nashville
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Toborzás folyamatban1. fázis
- Tennessee Oncology, Nashville
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Toborzás folyamatban1/2. fázis
- Research Site, Nashville
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Toborzás folyamatban2. fázis
- GSK Investigational Site, Nashville
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Toborzás folyamatban3. fázis
- Ascension St. Thomas Hospital, Nashville
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers, Nashville
- és további 2
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
Toborzás folyamatban2. fázis
- Vanderbilt University Medical Center, Nashville
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Toborzás folyamatban1/2. fázis
- GSK Investigational Site, Nashville
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Toborzás folyamatban1. fázis
- Tennessee Oncology, Nashville
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Toborzás folyamatban1/2. fázis
- SCRI Oncology Partners, Nashville
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Toborzás folyamatban1/2. fázis
- Research Site, Nashville
- Research Site, Nashville
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Toborzás folyamatban3. fázis
- Research Site, Nashville
- Research Site, Nashville
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Toborzás folyamatban2. fázis
- Tennessee Oncology, Nashville
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Toborzás folyamatban1. fázis
- Tennessee Oncology, Nashville
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Toborzás folyamatban1. fázis
- Vanderbilt Ingram Cancer Center /ID# 252470, Nashville
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Toborzás folyamatban3. fázis
- Vanderbilt-Ingram Cancer Center (VICC), Nashville
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Toborzás folyamatban2. fázis
- SCRI Oncology Partners, Nashville
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Toborzás folyamatban2. fázis
- TriStar Bone Marrow Transplant, Nashville
- Vanderbilt- Ingram Cancer Center, Nashville
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Toborzás folyamatban1/2. fázis
- TriStar Centennial Medical Center, Nashville
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Toborzás folyamatban1. fázis
- Local Institution - 0008, Nashville
- Tennessee Oncology, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Toborzás folyamatbanMegfigyeléses tanulmányEgészséges önkéntesek is jelentkezhetnek
- Vanderbilt-Ingram Cancer Center, Nashville
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Toborzás folyamatban1. fázis
- Tennessee Oncology, Nashville
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Toborzás folyamatban1/2. fázis
- SCRI Oncology Partners, Nashville
Multiplex mielóma vizsgálatok más városokban
- New York City, NY60 tanulmány
- Boston, MA42 tanulmány
- Atlanta, GA42 tanulmány
- Houston, TX38 tanulmány
- Durham, NC37 tanulmány
- Denver, CO27 tanulmány
- Rochester, MN24 tanulmány
- St. Louis, MO24 tanulmány
- Columbus, OH24 tanulmány
- Baldwin Park, CA23 tanulmány
- Edison, NJ22 tanulmány
- Chicago, IL22 tanulmány
Egyéb vizsgálatok: Nashville
- Nem kis sejtes tüdőrák97 tanulmány
- Mellrák81 tanulmány
- Áttétes rák70 tanulmány
- Kolorektális rák69 tanulmány
- Rák (minden típus)65 tanulmány
- Petefészekrák49 tanulmány
- Prosztatarák43 tanulmány
- Tüdőrák40 tanulmány
- Fej- és nyaki laphámrák39 tanulmány
- Hasnyálmirigyrák39 tanulmány
- Endometriális rák38 tanulmány
- Melanóma33 tanulmány
Forrás: ClinicalTrials.gov, adatok lekérve: 2026. okt. 6.. Minden vizsgálat saját alkalmassági feltételeket határoz meg; a döntést a vizsgálati csapat hozza meg.